TAG:
laboratories
Ampersand Buys Calloway Labs, Enters Pain Management Market
By Robert Michel | From the Volume XIX No. – October 8, 2012 Issue
URINE DRUG TESTING for pain management may be a challenging business for clinical labs given that compliance officers in the states and in the federal government have successfully pursued lab compliance abuses in this line of business in recent years. Now comes news that private equity firm …
October 8, 2012 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XIX No. – October 8, 2012 Issue
Definiens AG, one of the major players in the fast-growing market for digital pathology, raised $12.8 million in additional capital funding. The company, based in Munich, Germany, manufacturers systems for digital image analysis. Definiens stated that the new funds will be used for â…
IOM Endorses Continuous Improvement, Lean
By R. Lewis Dark | From the Volume XIX No. – October 8, 2012 Issue
IT IS ONE OF THE IRONIES OF HEALTHCARE that it has taken the prestigious Institute of Medicine (IOM) more than three decades to fully recognize the necessary and essential role that continuous improvement and the associated disciplines of Lean, Six Sigma, and process improvement must…
CLMA Asks Labs for Examples of RAC Auditor Overreach
By Joseph Burns | From the Volume XIX No. 13 – September 17, 2012 Issue
STORIES ABOUT HOW PRIVATE MEDICARE AUDITORS are overreaching in their zeal to identify fraud have caught the attention of the U.S. Senate Finance Committee. It is asking providers to submit examples of overzealous RAC auditors. For its part, the Clinical Laboratory Management Association …
In Medicare Bull’s Eye: Lab Test Reimbursement
By R. Lewis Dark | From the Volume XIX No. 13 – September 17, 2012 Issue
YOU CAN CONSIDER THIS ISSUE OF THE DARK REPORT TO BE an early warning of the escalating effort by public and private payers to rein in the “soaring cost†of clinical laboratory testing and anatomic pathology services. The intelligence briefings you will read on the following pag…
Labs Have Questions about Prostate Biopsy Policy
By Joseph Burns | From the Volume XIX No. 13 – September 17, 2012 Issue
CEO SUMMARY: How will pathology laboratories respond to the publication of revised policies in how laboratories should file Medicare Part B claims for prostate biopsies? Not only will there be a sharp drop in the reimbursement paid for a 12-core prostate biopsy, but labs may be at increas…
Changed Medicare Policy Adds to Regulatory Risk
By Joseph Burns | From the Volume XIX No. 13 – September 17, 2012 Issue
CEO SUMMARY: When Medicare’s National Correct Coding Initiative (NCCI) manual took effect on January 1, 2012, it contained a significant change in how prostate biopsy claims are to be coded. This change was widely overlooked by the pathology profession and even dismissed entirely for it…
Lawyer Advises on Risk Of Prostate Biopsy Audits
By Joseph Burns | From the Volume XIX No. 13 – September 17, 2012 Issue
CEO SUMMARY: For labs currently processing prostate biopsy cases with five or more cores and for those pathologists interpreting those cases, there is a lack of clarity about new Medicare policies. As one example, risk of an audit is significant because of recent guidance issued by one Me…
Lab Specimen Transport Eliminates Need for Ice
By Joseph Burns | From the Volume XIX No. 13 – September 17, 2012 Issue
CEO SUMMARY: Because of its unique design and reliability, a new product for transporting laboratory specimens and units of blood without the use of ice and dry ice is gaining favor with innovative laboratories across the country. Kaiser Permanente of the Mid-Atlantic States uses this ice…
Competitive Bidding: Once Again, It’s Back!
By Robert Michel | From the Volume XIX No. 13 – September 17, 2012 Issue
CEO SUMMARY: For the clinical lab industry, the concept of competitive bidding for Medicare Part B Clinical Lab Testing may be like the movie “Groundhog Day.†The hero, Bill Murray, kept reliving the same day over and over. So it seems to be with competitive bidding. In the latest rep…
CURRENT ISSUE

Volume XXXII, No. 12 – August 25, 2025
In an exclusive interview, a laboratory industry M&A specialist discusses what’s driving lab outreach sales to national lab companies. Also, The Dark Report analyzes ways in which pathology and clinical labs can profitably partner with pharmaceutical companies.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized